We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte Inc on Thursday said profit fell in the third quarter despite revenue growth, as costs increase more than 80% ...
MaxCyte, Inc. 07 November 2024 MaxCyte announces filing of Form 10-Q for the quarterly period ended September 30, 2024 ROCKVILLE, MD, November 7, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE:...
MaxCyte, Inc. 07 November 2024 MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, November 7, 2024 - MaxCyte, Inc. (NASDAQ: MXCT;...
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD, November 6, 2024 — MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering...
ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
MaxCyte, Inc. 06 November 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD, November 6, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a...
MaxCyte, Inc. 04 November 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights ROCKVILLE, MD, November 4, 2024: MaxCyte Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...
MaxCyte, Inc. 31 October 2024 MaxCyte to Participate in Two Upcoming Investor Conferences Rockville, MD, Oct. 31, 2024 - MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1 | -0.36231884058 | 276 | 276 | 260 | 63131 | 272.36941598 | DE |
4 | -17 | -5.82191780822 | 292 | 303 | 260 | 49455 | 278.83061203 | DE |
12 | -50 | -15.3846153846 | 325 | 330 | 260 | 26853 | 284.0850704 | DE |
26 | -95 | -25.6756756757 | 370 | 405 | 260 | 19007 | 308.08851652 | DE |
52 | -10 | -3.50877192982 | 285 | 420 | 260 | 28204 | 347.66702906 | DE |
156 | -655 | -70.4301075269 | 930 | 945 | 172.5 | 41595 | 452.83173255 | DE |
260 | 165 | 150 | 110 | 1230 | 110 | 84271 | 560.90683388 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions